Vivani Medical(VANI) - 2024 Q3 - Quarterly Results

Financial Position - Vivani Medical announced a $5 million equity financing, securing its financial position into late 2025 to support the completion of its first-in-human study and data read-out[1]. - The company reported a cash balance of$21.0 million as of September 30, 2024, down from $26.3 million as of June 30, 2024, primarily due to a net loss of$6.0 million[9]. Operating Expenses - Research and development expenses for Q3 2024 were $4.2 million, a decrease of 5$4.4 million in Q3 2023, attributed to staffing reductions and reduced use of outside services[10]. - General and administrative expenses decreased by 22% to $2.1 million in Q3 2024 from$2.7 million in Q3 2023, due to staffing reductions and lower professional service costs[11]. - Total operating expenses for the three months ended September 2024 were $6,309,000, a decrease of 11.7$7,144,000 in the same period of 2023[19]. - Total operating expenses for the nine months ended September 2024 were $18,217,000, down from$20,748,000 in the same period of 2023, reflecting a decrease of 12.2%[19]. - The company continues to focus on reducing operating expenses while managing research and development costs effectively[19]. Net Loss - The net loss for Q3 2024 was $6.0 million, an improvement from a net loss of$6.8 million in Q3 2023, reflecting a decrease in operating expenses[12]. - Net loss for the three months ended September 2024 was $6,041,000, compared to a net loss of$6,782,000 for the same period in 2023, reflecting a 10.9% improvement[19]. - Net loss per common share for the three months ended September 2024 was $(0.11), an improvement from$(0.13) in the same period of 2023[19]. - Net loss for the nine months ended September 2024 was $17,436,000, an improvement from$19,626,000 in the same period of 2023, indicating a reduction of 11.1%[19]. Clinical Studies and Pipeline - The company received regulatory approval to initiate its first-in-human clinical study, LIBERATE-1, in Australia, focusing on a miniature, ultra long-acting GLP-1 implant for obesity[2][4]. - Vivani plans to initiate the LIBERATE-1 study in Q4 2024, with data projected to be available in 2025[7]. - The GLP-1 implant demonstrated an 82% liver fat reduction in an obese mouse model from a single administration, with expected twice-yearly dosing[5]. - The company’s emerging pipeline includes the NPM-139 semaglutide implant, which has the potential for once-yearly administration[13]. Market Context - Medication non-adherence contributes to over $500 billion in annual avoidable healthcare costs in the U.S., highlighting the need for Vivani's innovative drug delivery solutions[13].